Nuvectis Pharma Inc

Nuvectis Pharma is a biopharmaceutical company developing therapies for immune complement-related conditions and oncology. It currently reports no product revenue and funds operations through equity raises.

In 2026 it in-licensed ex-China rights to two compounds from Haisco Pharmaceutical Group:
- Ciprocopan (NXP100), its lead asset, is a once-daily oral Complement Factor B inhibitor. It was approved in China in July 2026 for complement-inhibitor-naïve PNH patients. A second Chinese application, for anti-C5-pretreated PNH, is under review. Chinese trials are ongoing in IgAN (Phase 3) and lupus nephritis (Phase 2). Nuvectis is discussing a U.S. regulatory path in PNH with the FDA and plans a U.S. IND for an additional indication.
- NXP200 is an oral, brain-penetrant 'paradox-breaker' BRAF inhibitor for BRAF V600X-mutated and Class II/III non-V600 solid tumors. It is in Phase 1b in glioma in China and holds Chinese Breakthrough Therapy Designation, with a U.S. IND planned.

The company also develops NXP900, an oral SRC/YES1 kinase inhibitor, in Phase 1b combination studies in EGFR+ and ALK+ non-small cell lung cancer and in pancreatic cancer. Quarter-end cash was about $140.7 million, which management expects to fund operations into 2H 2029. Updated Nov 4, 2026